STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2019

Summary

Stryker Corporation's third-quarter 2019 report shows robust top-line growth, with net sales increasing by 10.6% to $3.59 billion compared to the same period in 2018. This growth was driven by solid performance across all segments, particularly Neurotechnology and Spine, which saw a 19.4% increase in sales. The company also reported an 8.1% rise in gross profit to $2.33 billion, demonstrating effective cost management. Despite strong sales, net earnings decreased by 21.0% to $466 million, or $1.23 per diluted share, primarily due to higher recall charges and increased amortization of intangible assets stemming from recent acquisitions. However, adjusted net earnings per diluted share saw a healthy 13.0% increase, indicating strong operational performance excluding certain one-time items. The company maintained a strong balance sheet with total assets of $26.66 billion and a healthy current ratio, positioning it well for future growth and strategic initiatives.

Key Highlights

• 1Net sales increased by 10.6% to $3.59 billion in Q3 2019, with organic sales growth (excluding acquisitions and currency) of 9.3%.
• 2All three business segments (Orthopaedics, MedSurg, Neurotechnology and Spine) reported sales growth, with Neurotechnology and Spine showing the strongest performance at 19.4%.
• 3Gross profit increased by 8.1% to $2.33 billion, resulting in a gross margin of 65.0%, a slight decrease from 66.5% in the prior year.
• 4Net earnings decreased by 21.0% to $466 million, impacted by recall charges and amortization of intangible assets.
• 5Adjusted net earnings per diluted share increased by a strong 13.0% to $1.91, highlighting operational improvements.
• 6The company repaid $1.341 billion in debt during the first nine months of 2019, reducing its long-term debt.
• 7Cash flow from operations was $1.46 billion for the nine months ended September 30, 2019, down from $1.56 billion in the prior year period.

Frequently Asked Questions